Citi analyst Yigal Nochomovitz placed an “upside 90-day catalyst watch” on shares of Summit Therapeutics (SMMT) while keeping a Buy rating on the name with a $40 price target The company’s HARMONi-3 squamous cohort date in Q2 could “revitalize the stock” and bring a path to “rapid engagement” with the FDA, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs
- Summit Therapeutics reports Q4 adjusted EPS (14c), consensus (1c)
- Summit Therapeutics options imply 6.1% move in share price post-earnings
- SMMT Upcoming Earnings Report: What to Expect?
- Summit Therapeutics: Ivonescimab’s De-Risked Regulatory Path and Multi-Indication Upside Support $40 Target and Buy Rating